Actinium Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Park Ave Fl 23, New York City, New Y...Phone Number
(646) 677-3870Website
www.actiniumpharma.comRevenue
<$5 MillionStock Symbol
ATNMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT condRead more
Actinium Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actinium Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Actinium Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Actinium Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Check if Actinium Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Actinium Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Actinium Pharmaceuticals has new funding data
Check out if Actinium Pharmaceuticals is spiking on competitors!
Actinium Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Actinium Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Actinium Pharmaceuticals
Compare insights from companies similar to Actinium Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Actinium Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Actinium Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actinium Pharmaceuticals.
Actinium Pharmaceuticals Tech Stack
A closer look at the technologies used by Actinium Pharmaceuticals
Most Recent Scoops
Left Company
Executive Move
As previously announced, Stephen O'Loughlin, Chief Financial Officer, has recently left the company.
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Partnership
Actinium Pharmaceuticals has announced that it is seeking potential partnerships for its Actimab A phase two, three trial, the IMMP program, and other assets.
Partnership, Research & Development, Medical Research
Project
Actinium Pharmaceuticals has announced that its lead clinical program, Actimab A, targets CD33 on various blood cancer cells using a CD33 targeting antibody labeled with the Actinium-225 radioisotope. This alpha emitter provides high energy output for precise cancer cell killing with minimal off-target effects.
Research & Development, Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actinium Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease o... Read More
